Ryan Dittamore
Overview
Explore the profile of Ryan Dittamore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1866
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Graf R, Hullings M, Barnett E, Carbone E, Dittamore R, Scher H
Eur Urol
. 2019 Oct;
77(2):170-177.
PMID: 31648903
Background: Proof of the clinical utility of a biomarker is when its use informs a management decision and improves patient outcomes relative to when it is not used. Objective: To...
12.
Friedlander T, Welty C, Anantharaman A, Schonhoft J, Jendrisak A, Lee J, et al.
J Urol
. 2019 Jun;
202(4):732-741.
PMID: 31216253
Purpose: Approximately 15% of men with newly diagnosed prostate cancer have high risk features which increase the risk of recurrence and metastasis. Better predictive biomarkers could allow for earlier detection...
13.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, et al.
Sci Transl Med
. 2019 Mar;
11(484).
PMID: 30894499
Histologic transformation to small cell neuroendocrine prostate cancer occurs in a subset of patients with advanced prostate cancer as a mechanism of treatment resistance. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug...
14.
Armstrong A, Halabi S, Luo J, Nanus D, Giannakakou P, Szmulewitz R, et al.
J Clin Oncol
. 2019 Mar;
37(13):1120-1129.
PMID: 30865549
Purpose: Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamide. Given...
15.
Bamford P, Dittamore R, Scher H
JAMA Oncol
. 2019 Feb;
5(3):434.
PMID: 30703186
No abstract available.
16.
Karzai F, VanderWeele D, Madan R, Owens H, Cordes L, Hankin A, et al.
J Immunother Cancer
. 2018 Dec;
6(1):141.
PMID: 30514390
Background: Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by...
17.
Boudadi K, Suzman D, Anagnostou V, Fu W, Luber B, Wang H, et al.
Oncotarget
. 2018 Jul;
9(47):28561-28571.
PMID: 29983880
AR-V7-expressing metastatic prostate cancer is an aggressive phenotype with poor progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests that AR-V7-positive tumors may be enriched for DNA-repair defects, perhaps...
18.
Autio K, Dreicer R, Anderson J, Garcia J, Alva A, Hart L, et al.
JAMA Oncol
. 2018 Jul;
4(10):1344-1351.
PMID: 29978216
Importance: Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)-targeted nanoparticles is clinically effective, and the selective reduction of PSMA-positive circulating tumor cells (CTCs) after treatment has implications...
19.
Scher H, Graf R, Schreiber N, Jayaram A, Winquist E, McLaughlin B, et al.
JAMA Oncol
. 2018 Jun;
4(9):1179-1186.
PMID: 29955787
Importance: A blood test to determine whether to treat patients with metastatic castration-resistant prostate cancer (mCRPC) with an androgen receptor signaling (ARS) inhibitor or taxane is an unmet medical need....
20.
Fujii T, Reuben J, Huo L, Fernandez J, Gong Y, Krupa R, et al.
PLoS One
. 2017 Sep;
12(9):e0185231.
PMID: 28957377
Purpose: Androgen receptor (AR) is frequently detected in breast cancers, and AR-targeted therapies are showing activity in AR-positive (AR+) breast cancer. However, the role of AR in breast cancers is...